+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Europe Specialty Generics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

  • ID: 4763173
  • Report
  • April 2019
  • Region: Europe
  • 96 pages
  • IMARC Group
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
Europe specialty generics market reached a value of US$ 13.2 Billion in 2018. Specialty generics are classified as high-cost, high complexity and/or high touch generics. They are the generic versions of speciality branded drugs after they lose their patent protection. Specialty generics are used to treat complex diseases which may be chronic by nature and life-threatening like hepatitis C, cancer, rheumatoid arthritis, multiple sclerosis, etc.

Driven by factors such as an increasing aging population, changing lifestyles and a rising prevalence of chronic diseases, healthcare costs in Europe have increased significantly in recent years creating a huge burden on the government, healthcare providers and patients. Specialty generics are playing a major role in the region to reduce this cost burden as they are more cost-effective as compared to their branded versions. Unlike branded speciality drugs, specialty generics don’t require expensive and time-consuming research and development procedures. Additionally, they also don’t incur the same amount of marketing and promotional expenses, resulting in substantially lower costs. In addition to this, the patent expiration of several blockbuster specialty drugs is expected to expire in the coming years creating a positive impact on the market. Looking forward, the publisher expects the market value to reach US$ 21.9 Billion by 2024, exhibiting a CAGR of around 9% during 2019-2024.

Market Scope:

Historical, Current and Future Market Trends

Market Breakup by Region:

United Kingdom
Rest of Europe

Market Breakup by Route of Administration:


Market Breakup by Indication:

Autoimmune Diseases
Infectious Diseases

Market Breakup by Distribution Channel:

Retail Pharmacies
Specialty Pharmacies
Hospital Pharmacies

Competitive Landscape:

The leading players in the European specialty generics industry have also been examined in the report.

Key Questions Answered in This Report:
  • How has the European specialty generics market performed so far and how will it perform in the coming years?
  • What is the breakup of the European specialty generics market based on the region?
  • What is the breakup of the European specialty generics market based on the route of administration?
  • What is the breakup of the European specialty generics market based on the indication?
  • What is the breakup of European specialty generics market based on the distribution channel?
  • What are the various stages in the value chain of the specialty generics industry?
  • What are the key driving factors and challenges in the European specialty generics market?
  • What is the structure of the European specialty generics industry and who are the key players?
  • What is the degree of competition in the European specialty generics market?
Note: Product cover images may vary from those shown
2 of 3
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Global Specialty Generics Market: Introduction
4.1 What are Specialty Generic Drugs?
4.2 Types of Specialty Generics

5 Why are Specialty Generics So Lucrative?

6 Global Specialty Generics Market
6.1 Market Overview
6.2 Market Performance
6.3 Market Breakup by Route of Administration
6.4 Market Breakup by Indication
6.5 Market Breakup by Distribution Channel
6.6 Market Breakup by Region
6.7 Market Forecast

7 Europe Specialty Generics Market
7.1 Market Overview
7.2 Market Performance
7.3 Market Breakup by Route of Administration
7.4 Market Breakup by Indication
7.5 Market Breakup by Distribution Channel
7.6 Market Breakup by Region
7.7 Market Forecast
7.8 SWOT Analysis
7.8.1 Overview
7.8.2 Strengths
7.8.3 Weaknesses
7.8.4 Opportunities
7.8.5 Threats
7.9 Value Chain Analysis
7.10 Porters Five Forces Analysis
7.10.1 Overview
7.10.2 Bargaining Power of Buyers
7.10.3 Bargaining Power of Suppliers
7.10.4 Degree of Competition
7.10.5 Threat of New Entrants
7.10.6 Threat of Substitutes
7.11 Key Market Drivers and Success Factors

8 Market Breakup by Route of Administration
8.1 Injectable
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Oral
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.1 Market Forecast

9 Market Breakup by Indication
9.1 Oncology
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Autoimmune Diseases
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Infectious Diseases
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast

10 Market Breakup by Distribution Channel
10.1 Retail Pharmacies
10.1.1 Market Trends
10.1.2 Market Forecast
10.2 Specialty Pharmacies
10.2.1 Market Trends
10.2.2 Market Forecast
10.3 Hospital Pharmacies
10.3.1 Market Trends
10.3.2 Market Forecast

11 Market Breakup by Region
11.1 Italy
11.1.1 Market Trends
11.1.2 Market Forecast
11.2 Germany
11.2.1 Market Trends
11.2.2 Market Forecast
11.3 France
11.3.1 Market Trends
11.3.2 Market Forecast
11.4 United Kingdom
11.4.1 Market Trends
11.4.2 Market Forecast
11.5 Spain
11.5.1 Market Trends
11.5.2 Market Forecast
11.6 Rest of Europe
11.6.1 Market Trends
11.6.2 Market Forecast

12 Competitive Landscape
12.1 Market Structure
12.2 Key Players
12.3 Profiles of Key Players

*List of Tables and Figures are available on enquiry
Note: Product cover images may vary from those shown
3 of 3


4 of 3